Pathway Bioventures
Venture capitalChicago · Pre-Seed–Series A · 5 people tracked
Investment thesis
Pathway Bioventures focuses on early-stage precision therapeutics companies working on breakthrough life sciences innovations to address important unmet medical needs. The firm backs entrepreneurs pursuing advances in human health through novel therapeutics.
Source: firm website, verified Aug 3, 2026.
Team · 5 people
from the firm's websiteFounded Pathway Bioventures in 2018 and leads its operations, investments, diligence, and portfolio support. A cancer researcher with expertise in epidemiology, genomics, and RNA therapeutics; has served as board observer for several biotech firms and as EIR at Yale Ventures. Holds an MPH and PhD from Yale.
Partner focused on investments that bring scientific discoveries to the clinic, drawing on 15 years of experience across universities, startups, and early-stage investment groups. Co-founder and early employee of several therapeutics companies and founding CEO of Saros Therapeutics. Holds a PhD in Physics from Carnegie Mellon and an MBA from Chicago Booth.
Research Professor in Mechanical Engineering and Managing Director of the Center for Translational Research at CU Boulder, researching neural interfaces and prosthetic devices. Has founded three medical device companies and is CEO of Afference.
Biotechnology professional with a background in technology commercialization, program management, and drug development, with prior roles at Novartis Gene Therapies and ONK Therapeutics. Works with Pathway on new investment opportunities in gene editing, RNA therapeutics, and cancer therapies.
Founder and CEO of Radyus Research, a preclinical drug development research organization. An experienced drug developer and biotech investor with prior roles at Agent Capital, Baxter Ventures, and Baxalta Ventures. Holds a PhD in immunology and microbiology and an MBA from Northwestern.
What they invest in
from 8 of 28 portfolio companiesBiotech ×7Healthtech ×6Medical Devices ×4AI & Machine Learning ×2Deep Tech ×1Digital Health ×1Hardware ×1New Materials ×1
HQs:United States×6United Kingdom×1
Investments · 28 tracked
founders shown can be your intro pathSpecialist investor in advanced modalities including cell, gene, RNA, and targeted therapies
Afference develops neurotechnology that enables remote sensory perception through wearable devices, allowing people at a distance to share tactile sensations.
AI & Machine LearningDeep TechHardwareHealthtechCleveland, US
Jacob Segil(Co-founder & CEO)inDustin Tyler(Co-founder & CTO)inTaylor Hurst(Director)
BoardTrevor Zimmerman(Director)
Leverages neural engineering advances to create an artificial sense of touch
Pioneer in RNA editing therapeutics for rare and common diseases
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain.
BiotechMedical DevicesBoston, US
Developing first-in-class precision therapies for neurological disorders
Developing bispecific antibodies for precision autoimmune applications
Developing pan-gamma delta T cell engagers for solid and hematological cancers
Interrogates biomechanical properties of immune cells to rapidly diagnose sepsis and other severe immunological diseases
Cytovale develops microfluidic deformability cytometry technology for immune response diagnostics, with a focus on early detection and diagnosis in hospital settings.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Ajay Shah(Co-founder & CEO)inHenry Tse(Co-founder & Chief Technology Officer)inDino DiCarlo(Director, Promoter)Jack Fuchs(Director, Promoter)in
BoardLindy Fishburne(Director)
Creates advanced biomaterials and biofunctional 3D-printed implants for tissue regeneration and repair
Dimension Bio is a biotechnology company that designs and manufactures regenerative therapeutics using its BioNidum™ platform to restore tissue function lost to disease, trauma, or aging.
BiotechHealthtechNew Materials
Caralynn Nowinski Collens, M.D.(Co-founder & CEO)Ramille Shah, Ph.D.(Co-founder & CSO)
Developing ultra-selective proteasome inhibitors for oncology and autoimmune disease
Preclinical RNA-based therapeutics for severe neuromuscular diseases
Preclinical oral medicines that selectively kill cancer cells via direct DNA modification
Developing gene therapies for patients with severe kidney diseases
Computational biology and genetic medicine company developing RNA-based therapeutics for chronic liver diseases
Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.
AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB
Quin Wills(Founder/CSO)in
BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle
Clinical-stage company developing bacterial therapeutics for GI and neurological diseases
BiotechIndianopolis, US
Mark Heiman(Executive Officer)Joseph Trebley(Executive Officer, Director)James Schulz(Executive Officer, Director)Kevin Meyer(Executive Officer)
Simergent develops medical device systems for regulated healthcare markets, with expertise in peritoneal dialysis and infusion pump technologies.
BiotechHealthtechMedical DevicesChicago, US
Steve J. Lindo(Co-founder & CEO)Rick Pendergraft(Co-founder & Chief Technology Officer)Dr. James Sloand(Chief Medical Officer)Michael J Rohleder(Manager)Rick J Pendergraft(Manager)Steve J Lindo(Manager and Chief Executive Officer)
Building an automated peritoneal dialysis device for cheaper, safer, and smarter home-based dialysis
Frequently asked questions
- What stage does Pathway Bioventures invest at?
- Pathway Bioventures invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Pathway Bioventures focus on?
- Pathway Bioventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Pathway Bioventures located?
- Pathway Bioventures is headquartered in Chicago, US.
Similar investors
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.
Osage University Partners (OUP) is a venture capital firm that invests in startups emerging from leading research labs and universities, spanning technology and life sciences.
Sunstone Life Science Ventures is an independent European venture capital firm focused on early-stage life science companies developing novel therapeutics for humans.
Arboretum Ventures is a Midwest-based healthcare venture capital firm that invests in early-stage healthcare startups across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.
Epidarex Capital is a transatlantic venture capital firm focused on early-stage life science companies, backing founders building businesses in emerging innovation hubs.